Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is associated with a cascade of pathological events involving formation of amyloid-based neuritic plaques and tau-based neurofibrillary tangles, changes in brain structure and function, and eventually, cognitive impairment and functional disability. The precise sequence of when each of these disease markers becomes abnormal is not yet clearly understood. The present study systematically tested the relationship between classes of biomarkers according to a proposed model of temporal sequence by Jack et al. (Lancet Neurology 9:119–128, 2010). We examined temporal relations among four classes of biomarkers: CSF Aβ, CSF tau, neuroimaging variables (hippocampal volume, ventricular volume, FDG PET), and cognitive variables (memory and executive function). Random effects modeling of longitudinal data obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) was used to test hypotheses that putative earlier markers of AD predicted change in later markers, and that intervening markers reduced effects of earlier on later markers. Specifically, we hypothesized that CSF tau would explain CSF Aβ’s relation to neuroimaging and cognitive variables, and neuroimaging variables would explain tau’s relation to cognitive variables. Consistent with hypotheses, results indicated that CSF Aβ effects on cognition change were substantially attenuated by CSF tau and measures of brain structure and function, and CSF tau effects on cognitive change were attenuated by neuroimaging variables. Contrary to hypotheses, CSF Aβ and CSF tau were observed to have independent effects on neuroimaging and CSF tau had a direct effect on baseline cognition independent of brain structure and function. These results have implications for clarifying the temporal sequence of AD changes and corresponding biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Cole, D. A., & Maxwell, S. E. (2003) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.112.4.558 · Cited by 3,605 · cited 2×
“Studies in which proposed mediator variables are measured longitudinally are especially valuable because they can be used to evaluate how change in the final outcome is mediated by change in intervening variables (Cole and Maxwell 2003; MacKinnon et al. 2007; Maxwell and Cole 2007).”
BackgroundLinear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
Bias in cross-sectional analyses of longitudinal mediation
Maxwell, S. E., & Cole, D. A. (2007) · Psychological Methods · doi:10.1037/1082-989x.12.1.23 · Cited by 3,401 · cited 6×
“Studies in which proposed mediator variables are measured longitudinally are especially valuable because they can be used to evaluate how change in the final outcome is mediated by change in intervening variables (Cole and Maxwell 2003; MacKinnon et al. 2007; Maxwell and Cole 2007).”
BackgroundInfluentialAlzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Self-citationAlzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 2×
“5 million persons in the US (Hebert et al. 2003), and by the year 2050, it is predicted to affect more than 13.”
BackgroundInfluentialAge, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
Individual differences in rates of change in cognitive abilities of older persons.
Wilson, R. S., Beckett, L. A., Barnes, L. L., Schneider, J. A., Bach, J., Evans, D. A., & Bennett, D. A. (2002) · Psychology and Aging · doi:10.1037/0882-7974.17.2.179 · Cited by 842 · cited 4×
“The well-documented heterogeneity in longitudinal trajectories as people age (Mungas et al., 2010, Wilson et al., 2002) presents a challenge in terms of finding variables that explain and predict who will and will not lose cognitive ability.”
BackgroundInfluentialSelf-citationStaging of Alzheimer-Related Cortical Destruction
Braak, H., Braak, E., & Bohl, J. (2008) · European Neurology · doi:10.1159/000116984 · Cited by 836 · cited 1×
“For example, the highly influential Braak and Braak model for staging of AD neuropathology (Braak et al. 1993) could be tested using longitudinal, in-vivo data to address progression of changes in region-specific medial temporal and neocortical brain measures, how they relate to CSF Aβ and tau, and how they correspond…”
BackgroundComparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000110315.26026.ef · Cited by 827 · cited 1×
“Evidence also suggests that FDG-PET changes (de Leon et al., 2001) and even structural brain changes such as hippocampal atrophy and increases in ventricular size (Jack et al., 2004) may precede cognitive changes in AD.”
Background
Cited by
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
“These results are in keeping with the model of Jack et al [14], which was subsequently empirically tested in a further paper by the same M.W. Weiner et al. / Alzheimer’s & Dementia 11 (2015) e1–e120e54 Variable name Annualized mean change by diagnosis Normal control MC Mean (SD) CV Mea CSF Ab242 20.94 (18) 1914 21.”
BackgroundMethodInfluentialSelf-citationHall, B., Mak, E., Cervenka, S., Aigbirhio, F. I., Rowe, J. B., & O’Brien, J. T. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.002 · Cited by 132
A critical review of chronic traumatic encephalopathy
Iverson, G. L., Gardner, A. J., McCrory, P., Zafonte, R., & Castellani, R. J. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.008 · Cited by 103
Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118645 · Cited by 96
van Waalwijk van Doorn, L. J. C., Gispert, J. D., Kuiperij, H. B., Claassen, J. A. H. R., Arighi, A., Baldeiras, I., Blennow, K., Bozzali, M., Castelo-Branco, M., Cavedo, E., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160668 · Cited by 13
Metadata
- Authors
- Initiative, F. T. A. D. N., Han, S. D., Gruhl, J., Beckett, L., Dodge, H. H., Stricker, N. H., Farias, S., & Mungas, D.
- Venue
- Brain Imaging and Behavior
- Published
- 2012-05-31
- Volume
- 6
- Issue
- 4
- Pages
- 610-620
- ISSN
- 1931-7557 (ISSN-L)
- 1931-7565
- OpenAlex
- W2003038500
- Cited by
- 62
- References
- 14
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s Disease. https://app.cochat.ai/papers/10.1007/s11682-012-9177-0
- The paper
- Initiative, F. T. A. D. N., Han, S. D., Gruhl, J., Beckett, L., Dodge, H. H., Stricker, N. H., Farias, S., & Mungas, D. (2012). Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s Disease. Brain Imaging and Behavior. https://doi.org/10.1007/s11682-012-9177-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.